**Supplementary Table 3.** Adherence and adverse events of second-line *H. pylori* eradication therapy

| Variable | 14-day rabeprazole-based bismuth-containing therapy (n=57) | 14-day tegoprazan-based bismuth-containing therapy (n=25) | *p*-value |
|---|---|---|---|
| Adherence* | | | 0.328 |
| Non-adherent | 10 (17.5) | 2 (8.0) | |
| Adherent | 47 (82.5) | 23 (92.0) | |
| Adverse event | | | |
| Any adverse events | 43 (75.4) | 17 (68.0) | 0.590 |
| General weakness | 5 (8.8) | 0 (0.0) | 0.316 |
| Dizziness | 4 (7.0) | 0 (0.0) | 0.308 |
| Headache | 1 (1.8) | 0 (0.0) | >0.999 |
| Myalgia | 1 (1.8) | 0 (0.0) | >0.999 |
| Acid regurgitation | 0 (0.0) | 0 (0.0) | N/A |
| Nausea & vomiting | 22 (38.6) | 7 (28.0) | 0.454 |
| Dysgeusia | 4 (7.0) | 2 (8.0) | >0.999 |
| Abdominal discomfort† | 5 (8.8) | 3 (12.0) | 0.695 |
| Abdominal pain | 0 (0.0) | 2 (8.0) | 0.090 |
| Diarrhea | 7 (12.3) | 2 (8.0) | 0.715 |
| Constipation | 1 (1.8) | 0 (0.0) | >0.999 |
| Skin rash | 0 (0.0) | 0 (0.0) | N/A |
| Others‡ | 8 (14.0) | 3 (12.0) | >0.999 |

Data are presented as n (%).
*Adherence is determined as administration of ≥80% of prescribed medications; †Abdominal discomfort include indigestion and bloating; ‡Other adverse events include sore on tongue, dry mouth, edema, palpitation, anal bleeding, and insomnia.
N/A, not applicable.